Introduction: Clinical Trial Registries Tracy J. BeckBarbara J. Godlew Clinical Trials 30 December 2010 Pages: 205 - 205
Clinical Trial Disclosure: Global Overview and Implications of New Laws and Guidelines Kathy B. ThomasMerete JoergensenClaudia Tesch Clinical Trials 30 December 2010 Pages: 213 - 225
The Emergence and Growth of Clinical Trial Information Transparency Pamela A. Rose Clinical Trials 30 December 2010 Pages: 227 - 232
ClinicalTrials.gov: A Questionnaire of Industry Experiences and Perceptions Katie McCarthyBarbara J. Godlew Clinical Trials 30 December 2010 Pages: 233 - 241
Clinical Trial Registration and Results Disclosure: Business Process Considerations Patricia Teden Clinical Trials 30 December 2010 Pages: 243 - 251
Operational Issues in Clinical Trial Disclosure of Global Trials Shown M. PelletierMaureen A. StrangeBarbara J. Godlew Clinical Trials 30 December 2010 Pages: 253 - 264
Transparency as a Means to Increase Clinical Trial Enrollment Barbara J. GodlewPatricia Furlong Clinical Trials 30 December 2010 Pages: 265 - 270
Can Clinical Trial Results Databases and Manuscripts Coexist? Tracy J. Beck Clinical Trials 30 December 2010 Pages: 271 - 277
Clinical Trial Registries: An Industry Perspective Lia McLean Clinical Trials 30 December 2010 Pages: 279 - 287
Global and Regional Drug Regulatory Harmonization Initiatives Maha M. Lakkis Regulatory Affairs 30 December 2010 Pages: 289 - 297
Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation Norbert BendaMichael BransonTim Friede Regulatory Affairs 30 December 2010 Pages: 299 - 315
Identifying and Rewarding Pharmaceutical Innovation: Application in an EU Member State Philippe Van WilderQi ZhuNoël Veraverbeke Regulatory Affairs 30 December 2010 Pages: 317 - 323
From Adaptive Design to Modern Protocol Design for Drug Development: Part I. Editorial and Summary of Adaptive Designs Session at the Third FDA/DIA Statistics Forum Sue-Jane WangFrank Bretz Statistics 30 December 2010 Pages: 325 - 331
From Adaptive Design to Modern Protocol Design for Drug Development: Part II. Success Probabilities and Effect Estimates for Phase 3 Development Programs Frank BrefzSue-Jane Wang Statistics 30 December 2010 Pages: 333 - 342
Primary Efficacy Endpoint in Clinical Trials of Antiepileptic Drugs: Change or Percentage Change Ohidul SiddiquiNorman Hershkowitz Statistics 30 December 2010 Pages: 343 - 350